GSK agrees $1.4 billion Aiolos Bio deal GSK today said it would acquire asthma drug maker Aiolos Bio in a deal worth up to $1.4 billion, as the British drugmaker boosts its growing respiratory diseases portfolio. Business • 09 Jan 24
GSK agrees $1.4 billion Aiolos Bio deal GSK today said it would acquire asthma drug maker Aiolos Bio in a deal worth up to $1.4 billion, as the British drugmaker boosts its growing respiratory diseases portfolio. Business • 09 Jan 24
